Through its partnership with Express Scripts Holding Co., Eli Lilly announced that certain patients will receive a discount of up to 40 percent on its insulin products.
The discount is designed for patients who pay full retail prices at the pharmacy. Next year, products purchased through prescription drug company Blink Health’s mobile and web platforms will be eligible for the discount. Previously, Blink Health only provided discounts on generic prescription drugs.
Lilly, Sanofi SA, Merck & Co Inc and Novo Nordisk A/S have been under scrutiny lately with U.S. lawmakers calling on federal antitrust regulators to probe if the aforementioned companies colluded to set prices for various diabetes drugs.
Just this past June, rivals Pfizer and Lilly increased the prices of their ED drugs nearly simultaneously.
Read the Bloomberg report